​

Arcturus Therapeutics (ARCT) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Arcturus Therapeutics Revenue Highlights

Latest Revenue (Y)

$152.31M

Latest Revenue (Q)

$29.38M

Main Segment (Y)

Collaboration Revenue

Main Geography (Y)

Foreign Countries

Arcturus Therapeutics Revenue by Period

Arcturus Therapeutics Revenue by Year

DateRevenueChange
2024-12-31$152.31M-3.45%
2023-12-31$157.75M-23.33%
2022-12-31$205.75M1564.82%
2021-12-31$12.36M29.56%
2020-12-31$9.54M-54.12%
2019-12-31$20.79M31.97%
2018-12-31$15.75M21.20%
2017-12-31$13.00M-36.23%
2016-12-31$20.38M232.06%
2015-12-31$6.14M100.00%
2014-12-31-100.00%
2013-12-31-100.00%
2012-12-31-100.00%
2011-12-31--

Arcturus Therapeutics generated $152.31M in revenue during NA 2024, up -3.45% compared to the previous quarter, and up 732.65% compared to the same period a year ago.

Arcturus Therapeutics Revenue by Quarter

DateRevenueChange
2025-03-31$29.38M39.91%
2024-12-31$21.00M-45.90%
2024-09-30$38.81M-15.58%
2024-06-30$45.98M41.04%
2024-03-31$32.60M15.55%
2023-12-31$28.21M-34.96%
2023-09-30$43.38M353.49%
2023-06-30$9.56M-88.00%
2023-03-31$79.73M-50.18%
2022-12-31$160.05M1097.17%
2022-09-30$13.37M-50.66%
2022-06-30$27.09M416.65%
2022-03-31$5.24M-9.49%
2021-12-31$5.79M137.75%
2021-09-30$2.44M21.79%
2021-06-30$2.00M-5.92%
2021-03-31$2.13M-4.96%
2020-12-31$2.24M-4.07%
2020-09-30$2.33M0.47%
2020-06-30$2.32M-12.24%
2020-03-31$2.65M-10.85%
2019-12-31$2.97M-10.55%
2019-09-30$3.32M-67.32%
2019-06-30$10.15M133.40%
2019-03-31$4.35M-42.59%
2018-12-31$7.58M121.36%
2018-09-30$3.42M43.46%
2018-06-30$2.39M0.80%
2018-03-31$2.37M-81.79%
2017-12-31$13.00M294.36%
2017-09-30$3.30M-12.36%
2017-06-30$3.76M-2.08%
2017-03-31$3.84M100.00%
2016-12-31-100.00%
2016-09-30-100.00%
2016-06-30-100.00%
2016-03-31-100.00%
2015-12-31-100.00%
2015-09-30-100.00%
2015-06-30-100.00%
2015-03-31-100.00%
2014-12-31-100.00%
2014-09-30-100.00%
2014-06-30-100.00%
2014-03-31-100.00%
2013-12-31-100.00%
2013-09-30-100.00%
2013-06-30-100.00%
2013-03-31-100.00%
2012-12-31-100.00%
2012-09-30-100.00%
2012-06-30--

Arcturus Therapeutics generated $29.38M in revenue during Q1 2025, up 39.91% compared to the previous quarter, and up 104.15% compared to the same period a year ago.

Arcturus Therapeutics Revenue Breakdown

Arcturus Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 23Dec 22
Grant$13.92M--
Collaboration Revenue$138.39M$157.75M$205.75M

Arcturus Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: Collaboration Revenue (90.86%), and Grant (9.14%).

Quarterly Revenue by Product

Product/ServiceMar 25Dec 24Sep 24Jun 24Mar 24Dec 23Jun 23Mar 23Jun 19
Grant$3.90M$1.77M$2.86M$3.88M$5.41M$954.00K$556.00K--
Collaboration Revenue$25.48M$21.00M$38.81M$45.98M$32.60M$78.02M$79.73M--
Other Collaboration Revenue--------$3.60M

Arcturus Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 25: Collaboration Revenue (86.71%), and Grant (13.29%).

Arcturus Therapeutics Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 24
Foreign Countries$138.40M

Arcturus Therapeutics's latest annual revenue breakdown by geography, as of Dec 24: Foreign Countries (100.00%).

Arcturus Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
BPMCBlueprint Medicines$508.82M$149.41M
MDGLMadrigal Pharmaceuticals$180.13M$137.25M
ARCTArcturus Therapeutics$152.31M$29.38M
DAWNDay One Biopharmaceuticals$131.16M$29.21M
GOSSGossamer Bio$114.70M$9.89M
ACLXArcellx$107.94M$15.27M
AMLXAmylyx Pharmaceuticals$87.37M$-665.00K
CRSPCRISPR Therapeutics$37.31M$35.00M
STOKStoke Therapeutics$36.55M$22.61M
FATEFate Therapeutics$13.63M$1.86M
NTLAIntellia Therapeutics-$12.87M
ETNB89bio--
AKROAkero Therapeutics--
BDTXBlack Diamond Therapeutics--
FDMT4D Molecular Therapeutics-$1.00K
CRBUCaribou Biosciences-$2.08M
BEAMBeam Therapeutics-$30.07M
PLRXPliant Therapeutics--
BMEABiomea Fusion--

ARCT Revenue FAQ

What is Arcturus Therapeutics’s yearly revenue?

Arcturus Therapeutics's yearly revenue for 2024 was $152.31M, representing a decrease of -3.45% compared to 2023. The company's yearly revenue for 2023 was $157.75M, representing a decrease of -23.33% compared to 2022. ARCT's yearly revenue for 2022 was $205.76M, representing an increase of 1564.82% compared to 2021.

What is Arcturus Therapeutics’s quarterly revenue?

Arcturus Therapeutics's quarterly revenue for Q1 2025 was $29.38M, a 39.91% increase from the previous quarter (Q4 2024), and a -9.87% decrease year-over-year (Q1 2024). The company's quarterly revenue for Q4 2024 was $21M, a -45.90% decrease from the previous quarter (Q3 2024), and a -25.56% decrease year-over-year (Q4 2023). ARCT's quarterly revenue for Q3 2024 was $38.82M, a -15.58% decrease from the previous quarter (Q2 2024), and a -10.52% decrease year-over-year (Q3 2023).

What is Arcturus Therapeutics’s revenue growth rate?

Arcturus Therapeutics's revenue growth rate for the last 3 years (2022-2024) was -25.98%, and for the last 5 years (2020-2024) was 1496.71%.

What are Arcturus Therapeutics’s revenue streams?

Arcturus Therapeutics's revenue streams in c 24 are Grant, and Collaboration Revenue. Grant generated $13.92M in revenue, accounting 9.14% of the company's total revenue Collaboration Revenue generated $138.39M in revenue, accounting 90.86% of the company's total revenue, down -12.27% year-over-year.

What is Arcturus Therapeutics’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Arcturus Therapeutics was Collaboration Revenue. This segment made a revenue of $138.39M, representing 90.86% of the company's total revenue.